Traws Pharma Inc (TRAW) Actualités

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program PR Newswire SAN DIEGO...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 424B4 - Prospectus [Rule 424(b)(4)]

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil...

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu PR Newswire NEWTOWN, Pa., Dec. 23, 2024 Investigational agent...